-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Platelet adhesion test
Platelet adhesion test(Platelet adhesiveness test, PAdT)
(Platelet adhesiveness test, PAdT)Normal value
Normal valueRotation method: 0.
Glass bead method: 0.
Influencing factors
Influencing factors1.
2.
3.
4.
Clinical interpretation
Clinical interpretation1.
Seen in hypercoagulable state or thrombotic diseases, such as myocardial infarction, venous or aortic embolism, hyperlipoproteinemia, atherosclerosis, hypertension, diabetes, certain cancers after surgery and oral contraceptives
2.
Seen in platelet weakness, von Willebrand disease (vWD), storage pool disease, mild platelet disease, collagen ineffective platelet disease, Hermansky-Pudiak syndrome, giant platelet syndrome, May-Hegglin abnormality, after taking aspirin and other drugs, Liver disease, uremia, leukemia, thrombocytosis, glycogen storage disease (type I), congenital fibrinogen deficiency, and after eating fish oil
Platelet aggregation test
Platelet aggregation test(Platelet aggregation test, PAgT)
(Platelet aggregation test, PAgT)Normal value
Normal value1.
2.
Influencing factors
Influencing factors1.
2.
3.
4.
5.
Because it is a turbidimetric method, it avoids the interference of hemolysis, red blood cell mixing, and lipid substances such as milk and soy milk
.
6.
Aspirin, dipyridamole, heparin, and dicoumarin drugs should not be used within 1 week before the test
.
7.
The platelet aggregation test is greatly affected by the environment and reagents of the day.
It is best to use normal human platelets as a control each time
.
8.
The effect of platelet aggregation increases as the concentration of sodium citrate in the plasma decreases.
Therefore, more anticoagulants should be added to patients with anemia than normal ones
.
9.
The specimens after blood collection should be placed at room temperature of 15~25℃.
Low temperature will increase the platelet activation and aggregation ability
.
Clinical interpretation
Clinical interpretation1.
Increased platelet aggregation: suggesting increased platelet activity, seen in post-surgery, diabetes, acute myocardial infarction, venous thrombosis, bruising congenital heart disease, pneumonia, hyper β lipoproteinemia, rejection of bone transplantation, artificial heart valve transplantation and multiple sclerosis
.
Oral contraceptives, high-fat diets, and smoking can also cause increased platelet aggregation
.
2.
Decreased platelet aggregation: suggesting platelet dysfunction, seen in platelet weakness (Glanzmann disease), primary and secondary platelet disease Bernard-Soulier syndrome, abnormal release response (reservoir disease), von Willebrand disease , May-Hegglin abnormality, Swisscheese disease, congenital hypofibrinogenemia, persistent and severe liver disease, Wilson disease, kidney disease (uremia), vitamin B12 deficiency, bacterial endocarditis, antiplatelet antibodyemia and Postoperative hypofibrinogenemia and so on
.
3.
The use of certain drugs, such as aspirin, dextran, phenylbutazone, etc.
, can reduce aggregation.
Therefore, the relevant drugs should be stopped before this test
.
Platelet thrombin sensitive protein
Platelet thrombin sensitive protein(Platelet thrompospondin, TSP)
(Platelet thrompospondin, TSP)Normal value
Normal value1.
Human plasma content
Enzyme-linked immunosorbent assay (ELISA method): (105.
0±31.
6) μg/L platelets
.
2.
Serum content
Enzyme-linked immunosorbent assay (ELISA method): (25.
3 ± 5.
70) μg/L platelets
.
3.
Whole blood content
Enzyme-linked immunosorbent test (ELISA method): (18.
0 ± 3.
39) μg/L platelets
.
4.
Platelet content
Enzyme-linked immunosorbent assay (ELISA method): (89.
1±28.
26) μg/L platelets
.
Influencing factors
Influencing factors1.
In the TSP test, attention should be paid to the in vitro activation of platelets, and the smooth blood collection should be emphasized
.
2.
Siliconization of glassware or the use of plastic products is necessary
.
Because glass can activate the coagulation reaction
.
3.
TSP can be released into the blood in large quantities due to the growth and metastasis of tumor cells, especially in adenocarcinoma
.
Clinical interpretation
Clinical interpretationIncreased TSP is seen in prethrombotic states and thrombotic diseases, such as acute myocardial infarction, unstable angina, diabetes with microangiopathy, hyperlipidemia, hypertension, cerebrovascular disease, deep vein thrombosis, DIC, nephrotic syndrome, pulmonary embolism, pregnancy and post-pregnancy toxemia
.
TSP is not as specific as β-TG and PF4
.
Platelet (plasma) surface α-granule membrane protein 140 detection
Platelet (plasma) surface α-granule membrane protein 140 detection[Platelet(plasma)α-gran-ule membrane protein 140, GMP-140]
[Platelet(plasma)α-gran-ule membrane protein 140, GMP-140]Normal value
Normal valueRadioimmunoassay (RIA method): (780±490) number of molecules/platelets
.
Radioimmunoassay (RIA method): (1.
61±0.
72) x1010 molecules/L plasma
.
Influencing factors
Influencing factors1.
It is best to use siliconized or plastic syringes, glass test tubes, etc.
, which need to be coated with silicon, because glass can activate the coagulation reaction
.
2.
The ideal anticoagulant should be sodium citrate
.
3.
The tourniquet should not be tied too tightly, preferably no more than 5 minutes, and it should be emphasized that the blood collection is smooth to prevent activation of the coagulation reaction
.
Clinical interpretation
Clinical interpretation1.
Reduce
Mainly seen in platelet weakness (deficiency of GPⅡb, GPⅡa), giant platelet syndrome (deficiency of GPⅠb, GPⅨ), primary thrombocytopenic purpura (platelet protein autoantibodies may be present in the body)
.
2.
Increase
In the prethrombotic state and thrombotic diseases, elevated GMP-140 can be used as a specific molecular marker of platelet activation
.
Plasma fibronectin
Plasma fibronectin(Plasma fibronectin, Fn)
(Plasma fibronectin, Fn)Normal value
Normal valueEnzyme-linked immunosorbent test (ELISA method): 277~513mg/L.
Influencing factors
Influencing factors1.
It is best to use siliconized or plastic syringes, glass test tubes, etc.
, which need to be coated with silicon, because glass can activate the coagulation reaction
.
2.
Pay attention to the preservation of specimens, preferably fresh specimens
.
3.
If it is not a fresh specimen, whether it is taken from -80°C or -20°C, it must be in 37°C clean water to avoid affecting the measurement results
.
4.
In order to prevent heparin and EDTA anticoagulant from forming cryoprecipitate or becoming unstable with Fn, it is better to use sodium citrate anticoagulant for blood samples
.
Clinical interpretation
Clinical interpretation1.
Increased plasma Fn concentration
It is found in acute hepatitis and chronic hepatitis, fatty liver, liver cirrhosis, obstructive jaundice, cerebrovascular disease, late pregnancy, pregnancy-induced hypertension, pancreatic cancer, lung cancer, cancerous ascites and adenocarcinoma with widespread metastasis
.
2.
Decreased plasma Fn concentration
Found in acute leukemia, DIC, acute severe hepatitis, burns, trauma, shock, bacterial or viral infections, acute respiratory distress syndrome, diabetes complicated by ketoacidosis, uremia, acute circulatory failure, menopausal women and some chemotherapy Poorly tolerated patients
.
Leave a message here